Cellectis (FRA:ZVAA) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:ZVAA Cellectis SA FRA:ZVAA
64 GF Score
Price €2.40
GF Value €3.00
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Cellectis Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

FRA:ZVAA
64GF Score
Cellectis SA FRA:ZVAA
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Cellectis (FRA:ZVAA) Overvalued in 2026?

Based on GuruFocus' analysis, Cellectis stock appears to be undervalued. The current stock price of €2.40 is trading 20% below its estimated GF Value™ of €3.00. GuruFocus considers Cellectis to be Modestly Undervalued.

Key valuation signals for FRA:ZVAA:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: €3.00 vs. price of €2.40 (20% below fair value)
  • GF Score™: 64/100 with 4 warning signs

No single metric tells the full story. See the FRA:ZVAA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cellectis Business Description

Address 8, rue de la Croix Jarry, Paris, FRA, 75013
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
64GF Score

Get the complete analysis for FRA:ZVAA

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.40
Price
€3.00
GF Value